Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dexamethasone as a probe for docetaxel clearance.
Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azéma J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roché H. Puisset F, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2004 Sep;54(3):265-72. doi: 10.1007/s00280-004-0823-0. Epub 2004 May 5. Cancer Chemother Pharmacol. 2004. PMID: 15133628 Clinical Trial.
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E. Terret C, et al. Among authors: lafont t. Clin Pharmacol Ther. 2000 Sep;68(3):270-9. doi: 10.1067/mcp.2000.109352. Clin Pharmacol Ther. 2000. PMID: 11014408 Clinical Trial.
Population pharmacokinetics of oxaliplatin.
Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013
Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.
Puisset F, Chatelut E, Sparreboom A, Delord JP, Berchery D, Lochon I, Lafont T, Roché H. Puisset F, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2007 Jul;60(2):305-8. doi: 10.1007/s00280-006-0385-4. Epub 2006 Nov 24. Cancer Chemother Pharmacol. 2007. PMID: 17124593
Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, Lochon I, Chatelut E. Ferron G, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2008 Sep;62(4):679-83. doi: 10.1007/s00280-007-0654-x. Epub 2007 Dec 15. Cancer Chemother Pharmacol. 2008. PMID: 18084764 Clinical Trial.
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E. Schmitt A, et al. Among authors: lafont t. J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855828
29 results